Driver mutation testing was performed in 65 patients: 91% harbored JAK2V617F, 3% harbored CALR type 1, 2% harbored MPL and 5% were triple negative; moreover, JAK2V617F was mutated in 27 out of 33 (82%) ET patients. The gene discussed is MPL; the disease is essential thrombocythemia.